|
Hutchmed (China) Ltd on Monday said a phase 3 trial evaluating the investigational use of sovleplenib met its primary endpoint. The Hong Kong-based developer of treatments for cancer and immunological diseases said the primary endpoint of trial ESLIM-01 is a durable response rate in adult patients with primary immune thrombocytopenia in China. Thrombocytopenia means someone’s platelet count in their blood is too low. It can be caused by viruses such as HIV, hepatitis C, Ebstein-Barr, mumps and rubella, among others. It can also be the result of nutrient deficiencies, liver disease or pregnancy. Sovleplenib is a novel, investigational, selective small molecule inhibitor for oral administration targeting the spleen tyrosine kinase, also known as Syk. It is used for the treatment of haematological malignancies and immune diseases. Chief Medical Officer Michael Shi said: ‘Sovleplenib offers a potential new treatment for patients with chronic adult primary immune thrombocytopenia who have received at least one prior therapy, a heterogeneous disease that can persist for years and where there remains a significant need for new treatments.’ Hutchmed China plans to submit the new drug applications around the end of the year. Hutchmed China shares were 1.5% higher at 213.73 pence each on Monday morning in London. Copyright 2023 Alliance News Ltd. All Rights Reserved.
|
